Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): First overview of complete data set.

Abstract

5584 Background: We present the first report of overall findings, with mature 1- and 2-year follow up (F/U), from LORHAN, a prospective, longitudinal, observational national registry of head and neck carcinoma (HNC) patients (pts). Dec. 1, 2009 marked the 4th anniversary of LORHAN and a major milestone of enrolling >3,500 pts, triggering this comprehensive analysis. Methods: Pts with newly diagnosed HNC, scheduled to receive radiotherapy (RT) or drug therapy, ≥18 years of age and who have provided written informed consent are eligible for enrollment. Results: As of Jan. 3, 2010, 3525 pts have been enrolled. Nearly 100 community (COM) and academic (ACA) sites from 35 states have enrolled pts in the registry. Of principal investigators participating in LORHAN, 22% designated their setting as ACA, 78% as COM. ACA centers accrued 65% of pts. Locked records (signed off by the investigator) are available as follows: baseline (n=2,924), initial cancer treatment (tx) (n=2,276), re-tx (n=380), year (yr)-1 F/U (n=1,304) and yr-2 F/U (n=497). Few pts (n=67) are lost to F/U. Compared to COM sites, ACA centers treated younger pts, more black and fewer white pts, pts with poorer performance status, fewer laryngeal but more oropharyngeal, paranasal sinus and nasal tumors, and more advanced disease (all p-values <0.05); other clinical features were similar. More than half (56%) of pts received concurrent chemoradiation (CRT), either following curative surgery (n=335), induction chemotherapy (n=67) or alone (n=813). IMRT was the most common form of RT delivered (83% overall) and was used more frequently at ACA centers (89% vs. 74%; p<0.0001). Most common cancer drugs delivered were single-agent cisplatin (49% of pts), cetuximab (21%) and carboplatin/paclitaxel (7%); cisplatin was used more often at ACA sites, while cetuximab was used more often in the COM (all p-values < 0.05). The 1- and 2-yr rates for locoregional control were 85% and 74% and for overall survival were 85% and 73%, respectively. Conclusions: LORHAN provides important insights regarding U.S. patterns of practice and tx outcomes for HNC pts. As the sample size grows, LORHAN will be increasingly suited for conducting hypothesis-driven, population-based research. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration MedNet Solutions Bristol-Myers Squibb, ImClone Systems, MedNet Solutions Bristol-Myers Squibb, Merck Serono Amgen, Cellectar, Genentech, ImClone Systems